Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.

Bright GM, Do MT, McKew JC, Blum WF, Thorner MO

Journal of the Endocrine Society25 Feb 2021Cited by 14 (Europe PMC)

PMID33982679PMCIDPMC8101275DOI10.1210/jendso/bvab030PepBankPUB-33982679

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanObservational studyEfficacy outcome
In prepubertal children with GHD, PEM-positive status identified better growth responses to LUM-201.
In plain wordsIn children with growth hormone deficiency, marker-positive status identified better growth responses to LUM-201 than marker-negative status.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseGrowth response by enrichment status
Study
n: not reported in source
Comparator
PEM-negative status
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · oral · 6 monthsAs given in this study (human).
Source sentences
Summary
PEM-positive status enriches a population for better growth responses to LUM-201.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed an analysis of a completed, randomized, placebo-controlled trial of LUM-201, a GH secretagogue receptor agonist, in which all randomized subjects had pretreatment testing.
Summary · context
This international multicenter study conducted in pediatric endocrinology clinics included 68 naïve-to-treatment, prepubertal children with established diagnoses of GHD.
Report a problemFND-3398267902

Studies that did not test the peptide alone1

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

02HumanNot a test of MK-677 (ibutamoren) aloneObservational studyOther
In prepubertal children with GHD, baseline IGF-I >30 ng/mL and peak GH ≥5 ng/mL after LUM-201 defined predictive enrichment positivity.
In plain wordsIn children with growth hormone deficiency, baseline IGF-I and the response to LUM-201 defined predictive enrichment markers.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicablePredictive enrichment markers
Study
n = 68
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Baseline IGF-I PEM threshold
> 30 ng/mL
PEM-positive criterion (1)
Peak GH response to single-dose LUM-201 PEM threshold
≥ 5 ng/mL
PEM-positive criterion (2)
Source sentences
Summary
Two PEM were identified for use in defining PEM-positive status: (1) baseline insulin-like growth factor I (IGF-I) concentration >30 ng/mL and (2) peak GH response of ≥5 ng/mL upon administration of single-dose LUM-201.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed an analysis of a completed, randomized, placebo-controlled trial of LUM-201, a GH secretagogue receptor agonist, in which all randomized subjects had pretreatment testing.
Summary · context
This international multicenter study conducted in pediatric endocrinology clinics included 68 naïve-to-treatment, prepubertal children with established diagnoses of GHD.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-3398267901

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.